SELF-REGULATION OF MEDICATION - HOW DO SCHIZOPHRENIC-PATIENTS MODIFY THEIR NEUROLEPTICS

被引:0
|
作者
HORNUNG, WP [1 ]
BUCHKREMER, G [1 ]
REDBRAKE, M [1 ]
KLINGBERG, S [1 ]
机构
[1] UNIV TUBINGEN,PSYCHIAT KLIN,W-7400 TUBINGEN 1,GERMANY
来源
NERVENARZT | 1993年 / 64卷 / 07期
关键词
SELF-REGULATION; NEUROLEPTICS; SCHIZOPHRENIA; CODETERMINATION;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
191 DSM-III-R schizophrenic outpatients were interviewed about their experiences in selfregulation of medication by means of a structured questionnaire. 59% of the 178 patients giving relevant replies claimed to have varied their neuroleptic dosage; i. e. augmented, reduced or discontinued it without consulting their doctor. Modifiers reported more often that their relatives were in favour of the medication, but less often that they themselves thought it important for their health. Augmenters were older on average than non-modifiers. Patients' appraisals of their experience appeared to be realistic, so that psychiatrists could make use of them to co-determine treatment in the individual case.
引用
收藏
页码:434 / 439
页数:6
相关论文
共 50 条
  • [1] DISORDERS OF SELF-REGULATION OF COGNITIVE ACTIVITY IN SCHIZOPHRENIC-PATIENTS
    ZEIGARNIK, BV
    KHOLMOGOROVA, AB
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 1985, 85 (12): : 1813 - 1819
  • [2] DO NEUROLEPTICS IMPAIR LEARNING IN SCHIZOPHRENIC-PATIENTS
    CUTMORE, TRH
    BENINGER, RJ
    SCHIZOPHRENIA RESEARCH, 1990, 3 (03) : 173 - 186
  • [3] NEUROLEPTICS AND CYTOKINE PRODUCTION IN SCHIZOPHRENIC-PATIENTS
    PIANCATELLI, D
    DELBEATO, T
    PELLEGRINI, P
    DIMICHELE, V
    CASACCHIA, M
    ADORNO, D
    CASCIANI, CU
    EOS-RIVISTA DI IMMUNOLOGIA ED IMMUNOFARMACOLOGIA, 1993, 13 (01): : 107 - 108
  • [4] DEBRISOQUINE OXIDATION IN SCHIZOPHRENIC-PATIENTS TREATED WITH NEUROLEPTICS
    SPINA, E
    BUEMI, AL
    CAPUTI, AP
    BENITEZ, J
    COBALEDA, J
    GARCIA, MA
    LLERENA, A
    PINA, B
    PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1988, 20 (12): : 1103 - 1104
  • [5] EFFECT OF NEUROLEPTICS ON SERUM PROLACTIN IN SCHIZOPHRENIC-PATIENTS
    MELTZER, HY
    FANG, VS
    ARCHIVES OF GENERAL PSYCHIATRY, 1976, 33 (03) : 279 - 286
  • [6] NEUROLEPTICS REVERSE ATTENTION ASYMMETRIES IN SCHIZOPHRENIC-PATIENTS
    TOMER, R
    FLORHENRY, P
    BIOLOGICAL PSYCHIATRY, 1989, 25 (07) : 852 - 860
  • [7] ROLE OF DEPOT NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIC-PATIENTS
    LEVINE, J
    SCHOOLER, NR
    CASSANO, GB
    PSYCHOLOGICAL MEDICINE, 1979, 9 (02) : 383 - 386
  • [8] THE EFFECTS OF NEUROLEPTICS ON FACIAL ACTION IN SCHIZOPHRENIC-PATIENTS
    SCHNEIDER, F
    ELLGRING, H
    FRIEDRICH, J
    FUS, I
    BEYER, T
    HEIMANN, H
    HIMER, W
    PHARMACOPSYCHIATRY, 1992, 25 (05) : 233 - 239
  • [9] ABSENCE OF ACQUIRED TOLERANCE TO NEUROLEPTICS IN SCHIZOPHRENIC-PATIENTS
    PALMSTIERNA, T
    WISTEDT, B
    AMERICAN JOURNAL OF PSYCHIATRY, 1987, 144 (08): : 1084 - 1085
  • [10] HOW SCHIZOPHRENIC-PATIENTS CHANGE DURING 3 YEARS TREATMENT WITH DEPOT NEUROLEPTICS
    DENCKER, SJ
    FRANKENBERG, K
    LEPP, M
    LINDBERG, D
    MALM, U
    ACTA PSYCHIATRICA SCANDINAVICA, 1978, 57 (02) : 115 - 123